Compare Abeona Therapeutics Inc (ABEO) vs Plby Group Inc (PLBY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Plby Group Inc — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while Plby Group Inc trades at $1.15 (market cap $136.40M). The key difference: Abeona Therapeutics Inc is far larger — about 2.7× Plby Group Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Plby Group Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | PLBY | |
|---|---|---|
Market Cap | $373.32M | $136.40M |
Sector | Health | Consumer Cyclical |
52-Week High | $7.23 | $2.71 |
52-Week Low | $4.17 | $1.18 |
Enterprise Value | $228.22M | $284.21M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
PLBY trades at $1.18, down 6.35% today, reflecting ongoing volatility. The stock shows mixed signals with a bearish technical trend but bullish oscillators like RSI at oversold levels. Fundamentally, the company has improved its net loss significantly from -$278M in 2022 to -$13M in 2025, with revenue stabilizing around $121M. Recent news highlights inclusion in Russell indexes and a share repurchase program, signaling management confidence. Cash flow turned positive in 2024-2025 after years of negative operational cash flow, though high debt remains a concern.
The outlook is cautiously optimistic due to improving EBITDA and analyst buy ratings (75%), but risks include persistent net losses, high debt-to-asset ratio near 60%, and competitive pressures in leisure branding. Investment appeal hinges on continued margin improvement and debt management, with current valuation metrics like P/S of 1.05 suggesting potential if execution succeeds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Plby Group Inc
PLBY Group Inc is a pleasure and leisure company. The company's segment includes Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. It generates maximum revenue from the Direct-to-Consumer segment. Direct-to-Consumer operations include consumer products sold through third-party retailers or online direct-to-customer. Geographically, it derives a majority of revenue from the United States.
Read more on PLBY →
